PTCT
PTCT
NASDAQ · Biotechnology

Ptc Therapeutics Inc

$80.96
+1.98 (+2.51%)
Financial Highlights (FY 2026)
Revenue
1.63B
Net Income
641.20M
Gross Margin
97.3%
Profit Margin
39.4%
Rev Growth
+128.3%
D/E Ratio
0.51
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 97.3% 97.3% 60.4% 60.4%
Operating Margin 50.1% 45.1% 19.1% 18.3%
Profit Margin 39.4% 37.5% 16.6% 18.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.63B 1.17B 623.61M 650.14M
Gross Profit 1.58B 1.14B 376.75M 392.78M
Operating Income 814.25M 526.34M 119.04M 119.01M
Net Income 641.20M 414.48M 103.27M 119.61M
Gross Margin 97.3% 97.3% 60.4% 60.4%
Operating Margin 50.1% 45.1% 19.1% 18.3%
Profit Margin 39.4% 37.5% 16.6% 18.4%
Rev Growth +128.3% +35.3% +11.8% -7.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.11B 2.97B 693.46M 831.94M
Total Equity 2.17B 3.50M 3.87B 4.02B
D/E Ratio 0.51 848.93 0.18 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 837.54M 571.47M 195.81M 183.50M
Free Cash Flow 61.49M 67.39M